PRE-TESTING AND VACCINATION

For more detailed information on vaccinations, please see the CANIBD Vaccination Guide

Baseline ECG. In patients with pre-existing conditions, advice from a cardiologist should be sought.

Blood work (baseline CBC, renal and liver function)
Opthalmic assessment in patients with a history of diabetes, uveitis or retinal disease.

Ensure all immunizations are current. Refer to CANIBD Vaccination Guidelines for further information14

Contraindications: Last 6 months myocardial infarction, unstable angina, pectoris, stroke, transient ischemic attack, decompensated heart failure, Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemake,
immunocompromised, severe active infections, active malignancies

METHOD OF ADMINISTRATION

Oral

LOCATION

Home

DOSING

2 mg tablet once daily

Due to risk of transient decreases in heart rate, first dose cardiac monitoring recommended.

Hourly pulse and blood pressure for 4-hr period. ECG prior to and at the end of this 4-hr period is recommended.

Please refer to product monograph for additional information.

TIME REQUIRED

5 min

ROUTINE MONITORING

Baseline bloodwork: Liver enzymes, ECG and ophthalmic evaluation. Follow up blood work as clinically indicated.

Blood pressure should be monitored during treatment and managed appropriately.

Patients with a history of diabetes mellitus, uveitis or retinal disease undergo follow up ophthalmologic evaluations while receiving therapy.